New Zealand markets closed
  • NZX 50

    12,036.05
    +12.59 (+0.10%)
     
  • NZD/USD

    0.6496
    +0.0003 (+0.05%)
     
  • NZD/EUR

    0.5970
    +0.0015 (+0.26%)
     
  • ALL ORDS

    7,709.50
    +21.50 (+0.28%)
     
  • ASX 200

    7,493.80
    +25.50 (+0.34%)
     
  • OIL

    79.38
    -1.63 (-2.01%)
     
  • GOLD

    1,943.90
    -2.80 (-0.14%)
     
  • NASDAQ

    12,166.60
    +115.12 (+0.96%)
     
  • FTSE

    7,765.15
    +4.04 (+0.05%)
     
  • Dow Jones

    33,978.08
    +28.67 (+0.08%)
     
  • DAX

    15,150.03
    +17.18 (+0.11%)
     
  • Hang Seng

    22,688.90
    +122.12 (+0.54%)
     
  • NIKKEI 225

    27,382.56
    +19.81 (+0.07%)
     
  • NZD/JPY

    84.3200
    -0.0940 (-0.11%)
     

STERIS Second Quarter 2023 Earnings: Misses Expectations

STERIS (NYSE:STE) Second Quarter 2023 Results

Key Financial Results

  • Revenue: US$1.20b (flat on 2Q 2022).

  • Net loss: US$315.3m (down from US$69.8m profit in 2Q 2022).

  • US$3.15 loss per share (down from US$0.70 profit in 2Q 2022).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

STERIS Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 5.9% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for STERIS you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here